Version Française

Develop quality in the health,
social and medico-social field

Search

impression
Transparency Commitee Opinion

MEGACE

Active substance (DCI)
  • megestrol acetate

Reason for request
Re-assessment of the actual benefit at the request of the Transparency

Date 18 September 2013

Actual benefit

Faible Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.


Documents

English version

ATC Code
  • L02AB01
Laboratory / Manufacturer
SWEDISH ORPHAN BIOVITRUM

Presentation

MEGACE 160 mg, tablet
B/30 (CIP: 336 047-2)

Posted on Nov 22 2013

For more information

SEE ALSO